Aeglea Biotherapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Aeglea Biotherapeutics Inc
TickerSYRE
CIK #0001636282
CUSIP00773J202
SectorLife Sciences - Pharmaceutical Preparations
Address901 S Mopac Expressway, Ste 250 Barton Oaks Plaza One, Austin, TX 78746
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Spyre Therapeutics Inc 2023-12-27 180.0 M Exemption: 506(b) · Duration: One year or less · Finder's Fee: $10,800,000 · Revenue: Decline to Disclose
Aeglea Biotherapeutics Inc 2023-07-06 210.0 M Exemption: 506(b) · Duration: One year or less · Finder's Fee: $12,600,015 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001636282] 10-K
[0001636282] 10-Q
[0001636282] 3
[0001636282] 4
[0001636282] 5
[0001636282] 8-K
[0001636282] D
[0001636282] SC 13D
[0001636282] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Perceptive Advisors LLC Spyre Therapeutics Inc [2026-04-22] 0.0
Vanguard Group Inc Spyre Therapeutics Inc [2025-07-29] 0.0
Tang Capital Management LLC Spyre Therapeutics Inc [2025-05-01] 0.0
BlackRock Inc Spyre Therapeutics Inc [2024-11-08] 5.2
Deutsch Peter E Spyre Therapeutics Inc [2024-10-23] 6.99
BlackRock Inc Spyre Therapeutics Inc [2024-10-22] 5.2
RTW Investments LP Spyre Therapeutics Inc [2024-02-14] 6.2
Avoro Capital Advisors LLC Spyre Therapeutics Inc [2024-02-14] 5.9
FMR LLC Spyre Therapeutics Inc [2024-02-09] 0.0
Perceptive Advisors LLC Spyre Therapeutics Inc [2023-12-13] 7.2
Commodore Capital LP Spyre Therapeutics Inc [2023-12-01] 6.1
Deutsch Peter E Aeglea Biotherapeutics Inc [2023-11-14] 0.48
Polar Capital Holdings PLC Aeglea Biotherapeutics Inc [2023-07-28] 5.02
Logos Global Management LP Aeglea Biotherapeutics Inc [2023-07-18] 8.1
Venrock Healthcare Capital Partners III LP Aeglea Biotherapeutics Inc [2023-07-10] 0.99
Affinity Asset Advisors LLC Aeglea Biotherapeutics Inc [2023-07-03] 0.23
EcoR1 Capital Fund Qualified LP Aeglea Biotherapeutics Inc [2023-06-30] 6.4
Fairmount Funds Management LLC Aeglea Biotherapeutics Inc [2023-06-30] 19.99
Deep Track Capital LP Aeglea Biotherapeutics Inc [2023-06-30] 0.99
Baker Bros Advisors LP Aeglea Biotherapeutics Inc [2023-02-14] 9.9
Rock Springs Capital Management LP Aeglea Biotherapeutics Inc [2023-02-14] 5.55
Pictet Asset Management Sa Aeglea Biotherapeutics Inc [2023-02-03] 0.0
Integrated Core Strategies US LLC Aeglea Biotherapeutics Inc [2022-12-01] 4.7
BlackRock Inc Aeglea Biotherapeutics Inc [2022-06-09] 4.8
Nantahala Capital Management LLC Aeglea Biotherapeutics Inc [2022-02-14] 5.7
Pictet Asset Management Sa Aeglea Biotherapeutics Inc [2022-02-10] 5.0
Suvretta Capital Management LLC Aeglea Biotherapeutics Inc [2021-12-16] 5.2
Baker Bros Advisors LP Aeglea Biotherapeutics Inc [2021-03-05] 0.9
Lilly Ventures Fund I LLC Aeglea Biotherapeutics Inc [2021-02-12] 5.4
Pictet Asset Management Sa Aeglea Biotherapeutics Inc [2021-02-10] 5.25
BlackRock Inc Aeglea Biotherapeutics Inc [2021-02-02] 6.8
Point72 Asset Management LP Aeglea Biotherapeutics Inc [2020-10-26] 6.2
BCLS II Equity Opportunities LP Aeglea Biotherapeutics Inc [2020-06-09] 6.1
BlackRock Inc Aeglea Biotherapeutics Inc [2019-02-08] 5.4
Adage Capital Partners GP LLC Aeglea Biotherapeutics Inc [2018-10-11] 6.61
Baker Bros Advisors LP Aeglea Biotherapeutics Inc [2018-02-13] 6.8
Nantahala Capital Management LLC Aeglea Biotherapeutics Inc [2017-12-08] 10.9
Lilly Ventures Fund I LLC Aeglea Biotherapeutics Inc [2017-02-14] 19.1
Prudential Financial Inc Aeglea Biotherapeutics Inc [2016-05-10] 10.7
Jennison Associates LLC Aeglea Biotherapeutics Inc [2016-05-09] 10.7
OrbiMed Advisors LLC Aeglea Biotherapeutics Inc [2016-04-18] 10.14
Novartis BioVentures Ltd Aeglea Biotherapeutics Inc [2016-04-14] 17.2
Form 3/4/5 Filer 2011 - 2026
Spyre Therapeutics Inc
Burrows Scott L
Sloan Sheldon
Turtle Cameron
Kiselak Tomas
Fairmount Funds Management LLC
Harwin Peter Evan
Fairmount Healthcare Fund II LP
Henderson Michael Thomas
McKenna Mark C
Milligan Sandra
Stelzer Laurie
Albers Jeffrey W
King-Jones Heidy
Fairmount Healthcare Co-Invest LP
Fairmount Healthcare Fund LP
Smith Hunter C
Alspaugh Jonathan
Cox Russell J
Magovcevic-Liebisch Ivana
Lawton Alison Frances
Hanley Jr Michael Conick
Neuman Linda L
Kastenmayer James Paul
Goldberg Jeff Marc
Souza Marcio
Sloan Leslie
Mahatme Sandesh
Lawlis V Bryan
Shanafelt Armen
Quinn Anthony
Weber Steven
Baker Brothers Life Sciences LP
Baker Bros Advisors GP LLC
667 LP
Baker Julian
Baker Felix
Baker Bros Advisors LP
Brownstein Sara
Bruhn Suzanne Louise
Rao Madduri Ravin
York Charles N II
Schuchart Aaron
Wooldridge James
Georgiou George
Novartis AG
Novartis BioVentures Ltd
Rowlinson Scott W
Tyler Joseph E
Hebel Henry
Lowe David George
Isaly Samuel D
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
Rojas-Caro Sandra
Lilly Eli & Co
Lilly Ventures Fund I LLC
Torres S Edward
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Burrows Scott L
Stock Option (Right to Buy) · derivative
2026-03-03 Option exercise 2,500 $0.00
Burrows Scott L
Common Stock
2026-03-03 Option exercise 2,500 $14.50 36,250
Burrows Scott L
Common Stock
2026-03-03 Sell 200 $41.66 8,332
Burrows Scott L
Common Stock
2026-03-03 Sell 2,300 $40.56 93,288
Turtle Cameron
Common Stock
2026-03-02 Sell 5,900 $41.73 246,207
Turtle Cameron
Common Stock
2026-03-02 Sell 9,100 $42.49 386,659
Turtle Cameron
Common Stock
2026-02-02 Sell 957 $31.82 30,452
Turtle Cameron
Common Stock
2026-02-02 Sell 14,043 $32.87 461,593
Henderson Michael Thomas
Common Stock
2026-01-21 Other 63,227 $0.00
King-Jones Heidy
Stock Option (Right to Buy) · derivative
2026-01-09 Grant 140,000 $0.00
Burrows Scott L
Stock Option (Right to Buy) · derivative
2026-01-09 Grant 140,000 $0.00
Turtle Cameron
Stock Option (Right to Buy) · derivative
2026-01-09 Grant 528,000 $0.00
Sloan Sheldon
Stock Option (Right to Buy) · derivative
2026-01-09 Grant 140,000 $0.00
Turtle Cameron
Common Stock
2026-01-02 Sell 2,191 $31.79 69,652
Turtle Cameron
Common Stock
2026-01-02 Sell 100 $32.39 3,239
Turtle Cameron
Common Stock
2026-01-02 Sell 12,709 $30.47 387,243
Turtle Cameron
Common Stock
2025-12-01 Sell 4,005 $29.83 119,469
Turtle Cameron
Common Stock
2025-12-01 Sell 10,995 $28.73 315,886
Turtle Cameron
Common Stock
2025-11-03 Sell 28,155 $23.13 651,225
Turtle Cameron
Common Stock
2025-11-03 Sell 16,845 $23.66 398,553
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 199 81,660,620
2025-12-31 155 78,443,609
2025-09-30 139 64,146,573
2025-06-30 131 62,858,730
2025-03-31 131 62,197,905
2024-12-31 133 59,434,187
2024-09-30 121 51,003,716
2024-06-30 109 50,702,260
2024-03-31 103 31,666,421
2023-12-31 55 28,011,053
2023-09-30 28 3,258,043
Form 13F Holdings
Firm Period DFND Voting Shares
Moody Aldrich Partners LLC [2026-06-30] SOLE 18,515 42,458
Ellsworth Advisors LLC [2026-06-30] SOLE 0 16,553
PSP Research LLC [2026-06-30] SOLE 0 4,000
Farther Finance Advisors LLC [2026-06-30] SOLE 0 1,129
Union Bancaire Privee UBP SA [2026-06-30] DFND 880 880
Gamma Investing LLC [2026-06-30] DFND 663 663
Handelsbanken Fonder AB [2026-06-30] SOLE 0 25
IFP Advisors LLC [2026-06-30] SOLE 24 24
Ares Financial Consulting LLC [2026-06-30] SOLE 11 11
Physician Wealth Advisors Inc [2026-06-30] SOLE 0 5
Hughes Financial Services LLC [2026-06-30] SOLE 4 4
MassMutual Private Wealth & Trust FSB [2026-06-30] SOLE 0 0
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com